In this article, we will discuss about Nilotinib (Dosage Overview). So, let’s get started.
Indications
Adult and Pediatric Patients With Newly Diagnosed Ph+CML-CP
Nilotinib (Tasigna®) is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Adult Patients with Resistant or Intolerant Ph+ CML-CP and CML-AP
Nilotinib (Tasigna®) is indicated for the treatment of adult patients with chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included imatinib.
Pediatric Patients with Resistant or Intolerant Ph+ CML-CP
Nilotinib (Tasigna®) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with chronic phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKT) therapy.
Dosage
Recommended Dosage
Dose Nilotinib (Tasigna®) twice daily at approximately 12-hour intervals on an empty stomach. No food should be
consumed for at least 2 hours before the dose is taken and for at least 1 hour after the dose is taken. Advise patients to swallow the capsules whole with water.
For patients who are unable to swallow capsules, the contents of each capsule may be dispersed in 1 teaspoon of applesauce (puréed apple). The mixture should be taken immediately (within 15 minutes) and should not be stored for future use.
Nilotinib (Tasigna®) may be given in combination with hematopoietic growth factors, such as erythropoietin or G-CSF if clinically indicated. Nilotinib (Tasigna®) may be given with hydroxyurea or anagrelide if clinically indicated.
Dosage in Adult Patients with Newly Diagnosed Ph-CML-CP
The recommended dosage of Nilotinib (Tasigna®) is 300 mg orally twice daily.
Dosage in Adlt Paients with Resistant or Intolerant Ph+ CML-CP and CML-AP
The recommended dosage of Nilotinib (Tasigna®) is 400 mg orally twice daily.
Dosage In Pedainc Patients with Newly Diagnosed Ph+ CML-CP or Resistant or Intolerant Ph+ CML-CP
The recommended dosage of Nilotinib (Tasigna®) for pediatric patients is 230 mg/m² orally twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg). If needed, attain the desired dose by combining different strengths of Nilotinib (Tasigna®) capsules. Continue treatment as long as clinical benefit is observed or until unacceptable toxicity occurs.